Dossier assessment
Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)
Report documents
-
Dossier assessment
Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)
Project details
- Project no.
- G23-14
- Commission
- Commission awarded on 03.07.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG, the GBA conducts a commenting procedure. Following the hearing, the GBA decides on the extent of the added benefit. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA Website.
Connected Projects
-
Dossier assessment
Selumetinib (treatment of neurofibromas in neurofibromatosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed